摘要
目的探讨阿立哌唑与利培酮治疗慢性精神分裂症的疗效及安全性。方法对50例慢性精神分裂症患者随机分为2组,分别给予阿立哌唑和利培酮治疗8周,采用阳性与阴性症状量表(PANSS)及副反应量表(TESS)在治疗前后1、2、4、8周末分别评定疗效和副反应。结果阿立哌唑组和利培酮组疗效间无显著性差异。TESS评定阿立哌唑组副作用小于利培酮组(P<0.01)。结论阿立哌唑与利培酮对慢性精神分裂症均有较好的疗效。阿立哌唑具有较小的副作用。
Objective To study the Curative effect and safety between aripiprazole and risperidone in the treatment of chronic schizophrenia panents. Methods 50 cases with schizophrenia were randomly divided into two groups receiving aripiprazole and risperidone respectively for 8 weeks. The Postive and Negtive Symptom Scale （PANSS） and Treatment Emergent Symptom Scale （TESS） were used to measure effectiveness and safety before treatment and at the end of the 1st, 2nd, 4th and 8th week respectively. Results There were no significant differences in effectiveness between two groups. TESS showed aripiprazole had less side effects than risperidone （P〈0.01）. Conclusion Aripiprazole was effective and safe neuroleptics.
出处
《中国健康心理学杂志》
2006年第6期650-651,共2页
China Journal of Health Psychology
